Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ppDC Vaccine + Nivolumab/Ipilimumab in H3 G34-Mutant Glioma
NCT05457959Phase 1Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in diffuse hemispheric glioma (DHG) (6 cohorts), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events. Planned start Dec 2024; status: withdrawn.
02
Conditions
diffuse hemispheric glioma (DHG)
Beyond the preview
Go deeper on NCT05457959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457959.